Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06916767 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
A Phase 1 study of Refractory Lymphoma and Relapsed CLL, sponsored by Paolo Caimi, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT06916767: Recruiting Phase 1 study of Refractory Lymphoma and Relapsed CLL, sponsored by Paolo Caimi, MD.
NCT06916767 is a Phase 1 study of Refractory Lymphoma and Relapsed CLL that is actively recruiting participants, run by Paolo Caimi, MD. The registered enrollment target is 18 participants, below the 36-participant average among 39 other Refractory Lymphoma trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06916767, a Phase 1 study of Refractory Lymphoma and Relapsed CLL, is actively recruiting participants, sponsored by Paolo Caimi, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
CAR-T cell treatment of refractory lymphoma has shown success, particularly with CD-19 targeted CAR-T cells, however, many participants are refractory or relapse after response. Responses are more limited in CLL/SLL, possibly secondary to the suppressive effect of circulating B cells on T cell function. BAFF receptor is a target that has been explored in CLL. Preclinical data indicates that CAR- T cells expressing B-cell activating factor (BAFF) can be another effective strategy to treat refractory CLL. This study aims to explore the efficacy of LMY-920 a BAFF-ligand CAR T cells with depletion of B cells with Obinutuzumab prior to apheresis.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG BAFF CAR-T
Study Locations (1)
Ohio
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT06916767 shows while recruiting
NCT06916767 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 36-participant average among 39 other Refractory Lymphoma trials with a reported enrollment target (50% lower).
The record links to 3 conditions, with Refractory Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Obinutuzumab is the first listed.
NCT06916767 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06916767 about?
NCT06916767 is a clinical study titled "Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma". CAR-T cell treatment of refractory lymphoma has shown success, particularly with CD-19 targeted CAR-T cells, however, many participants are refractory or relapse after response. Responses are more limited in CLL/SLL, possibly secondary to the suppressive effect of circulating B cells on T cell funct...
What is the current status of trial NCT06916767?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-07-15. Estimated completion is 2027-12-31.
What conditions does trial NCT06916767 study?
This clinical trial studies the following conditions: Refractory Lymphoma, Relapsed CLL, Refractory CLL.
What interventions are being tested in trial NCT06916767?
The interventions under investigation include: Obinutuzumab (DRUG), Cyclophosphamide (DRUG), Fludarabine (DRUG), BAFF CAR-T (DRUG).
Who is sponsoring clinical trial NCT06916767?
This trial is sponsored by Paolo Caimi, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06916767 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06916767's enrollment target sits among peer trials
18 35th of 39 higher than 5 of 39 other Refractory Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Avo In R/R And Previously Untreated MCL
RECRUITING · Phase 1
-
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
RECRUITING · Phase 1
-
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
COMPLETED · Phase 1
-
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
COMPLETED · Phase 1
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI